FOXO1 and cancer: Nevertheless, whether arzanol’s SIRT1 inhibition contributes to its anticancer effects requires cancer cell-specific studies examining SIRT1 and FOXO1 expression and activity following arzanol treatment, complemented measuring SIRT1 overexpression or comparison with selective SIRT1 inhibitors.